JP2022504638A5 - - Google Patents

Info

Publication number
JP2022504638A5
JP2022504638A5 JP2021519747A JP2021519747A JP2022504638A5 JP 2022504638 A5 JP2022504638 A5 JP 2022504638A5 JP 2021519747 A JP2021519747 A JP 2021519747A JP 2021519747 A JP2021519747 A JP 2021519747A JP 2022504638 A5 JP2022504638 A5 JP 2022504638A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
nephropathy
kidney
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504638A (ja
JP7203964B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055850 external-priority patent/WO2020077217A1/en
Publication of JP2022504638A publication Critical patent/JP2022504638A/ja
Publication of JP2022504638A5 publication Critical patent/JP2022504638A5/ja
Priority to JP2022209518A priority Critical patent/JP2023040106A/ja
Application granted granted Critical
Publication of JP7203964B2 publication Critical patent/JP7203964B2/ja
Priority to JP2025027546A priority patent/JP2025081607A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519747A 2018-10-11 2019-10-11 統合的ストレス経路のプロドラッグ調節剤 Active JP7203964B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209518A JP2023040106A (ja) 2018-10-11 2022-12-27 統合的ストレス経路のプロドラッグ調節剤
JP2025027546A JP2025081607A (ja) 2018-10-11 2025-02-25 統合的ストレス経路のプロドラッグ調節剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744293P 2018-10-11 2018-10-11
US62/744,293 2018-10-11
PCT/US2019/055850 WO2020077217A1 (en) 2018-10-11 2019-10-11 Prodrug modulators of the integrated stress pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209518A Division JP2023040106A (ja) 2018-10-11 2022-12-27 統合的ストレス経路のプロドラッグ調節剤

Publications (3)

Publication Number Publication Date
JP2022504638A JP2022504638A (ja) 2022-01-13
JP2022504638A5 true JP2022504638A5 (cg-RX-API-DMAC7.html) 2022-10-19
JP7203964B2 JP7203964B2 (ja) 2023-01-13

Family

ID=68387427

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021519747A Active JP7203964B2 (ja) 2018-10-11 2019-10-11 統合的ストレス経路のプロドラッグ調節剤
JP2022209518A Pending JP2023040106A (ja) 2018-10-11 2022-12-27 統合的ストレス経路のプロドラッグ調節剤
JP2025027546A Pending JP2025081607A (ja) 2018-10-11 2025-02-25 統合的ストレス経路のプロドラッグ調節剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209518A Pending JP2023040106A (ja) 2018-10-11 2022-12-27 統合的ストレス経路のプロドラッグ調節剤
JP2025027546A Pending JP2025081607A (ja) 2018-10-11 2025-02-25 統合的ストレス経路のプロドラッグ調節剤

Country Status (35)

Country Link
US (2) US11149043B2 (cg-RX-API-DMAC7.html)
EP (3) EP4209483B1 (cg-RX-API-DMAC7.html)
JP (3) JP7203964B2 (cg-RX-API-DMAC7.html)
KR (3) KR20220151232A (cg-RX-API-DMAC7.html)
CN (2) CN116283647A (cg-RX-API-DMAC7.html)
AR (2) AR116693A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019356565B2 (cg-RX-API-DMAC7.html)
CA (1) CA3115668A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000875A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006098A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230182A (cg-RX-API-DMAC7.html)
DK (1) DK3864003T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000064A (cg-RX-API-DMAC7.html)
EC (1) ECSP21032861A (cg-RX-API-DMAC7.html)
ES (2) ES3068314T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864003T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230222T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061297T2 (cg-RX-API-DMAC7.html)
IL (3) IL282153B2 (cg-RX-API-DMAC7.html)
LT (1) LT3864003T (cg-RX-API-DMAC7.html)
MA (1) MA53861B1 (cg-RX-API-DMAC7.html)
MD (1) MD3864003T2 (cg-RX-API-DMAC7.html)
MX (2) MX2021004163A (cg-RX-API-DMAC7.html)
MY (1) MY207223A (cg-RX-API-DMAC7.html)
PE (2) PE20211277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550786A1 (cg-RX-API-DMAC7.html)
PL (1) PL3864003T3 (cg-RX-API-DMAC7.html)
PT (1) PT3864003T (cg-RX-API-DMAC7.html)
RS (1) RS64013B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103531YA (cg-RX-API-DMAC7.html)
SI (1) SI3864003T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300058T1 (cg-RX-API-DMAC7.html)
TW (4) TW202545902A (cg-RX-API-DMAC7.html)
UY (1) UY38415A (cg-RX-API-DMAC7.html)
WO (1) WO2020077217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
TW202545902A (zh) * 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
WO2022102095A1 (ja) 2020-11-13 2022-05-19 国立大学法人静岡大学 放射線撮像装置
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
JP2024501994A (ja) * 2020-12-25 2024-01-17 上海盛迪医▲葯▼有限公司 Nk1拮抗剤プロドラッグ化合物と5-ht3受容体拮抗剤との併用使用
WO2023034510A1 (en) 2021-09-01 2023-03-09 ATAI Life Sciences AG Synthesis of mdma or its optically active ( r)- or ( s)-mdma isomers
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN118141794A (zh) * 2024-01-24 2024-06-07 同济大学 ISR抑制剂ISRIB在制备治疗Wolfram综合征的药物中的应用
WO2025230528A1 (en) * 2024-05-01 2025-11-06 Calico Life Sciences Llc Methods of treating amyotrophic lateral sclerosis

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212A (en) 1847-07-31 Richard m
US162A (en) 1837-04-17 Island
GB1026506A (en) 1962-10-17 1966-04-20 Du Pont Bicyclodiamines and preparation thereof
US3264351A (en) 1964-07-08 1966-08-02 American Home Prod 1, 4-diaminobicyclo [2.2.2] octanes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH02215779A (ja) 1989-02-14 1990-08-28 Kuraray Co Ltd カルボン酸アミド誘導体類及びその医薬用途
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5686454A (en) 1993-07-16 1997-11-11 Merck & Co., Inc. Camphorcarbonyl
DE60303441T2 (de) 2002-02-08 2006-09-21 Merck & Co., Inc. N-biphenylmethylaminocycloalkancarboxamid-derivative
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
JP2006520385A (ja) * 2003-03-13 2006-09-07 シンタ ファーマスーティカルズ コーポレイション 縮合ピロール化合物
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
AU2005212073B2 (en) 2004-02-18 2010-07-08 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
CA2594116A1 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
WO2008075196A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
TWI538905B (zh) 2010-12-22 2016-06-21 H 朗德貝克公司 雙環[3.2.1]辛基醯胺衍生物及其用途
WO2013161980A1 (ja) 2012-04-27 2013-10-31 東レ株式会社 シクロヘキサンジアミド誘導体及びその医薬用途
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
US9580459B2 (en) 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
WO2015038778A1 (en) 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
US20150362847A1 (en) 2014-06-13 2015-12-17 Canon Kabushiki Kaisha Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2018520992A (ja) 2015-05-05 2018-08-02 バイエル ファーマ アクチエンゲゼルシャフト アミドで置換されているシクロヘキサン誘導体
US20190022071A1 (en) 2015-08-31 2019-01-24 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
RU2018145734A (ru) 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN106349130B (zh) 2016-08-25 2018-01-23 潍坊大有生物化工有限公司 一种新的氟苯尼考的合成方法
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
HUE061505T2 (hu) * 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
CN108517001A (zh) 2018-05-17 2018-09-11 江苏恩华络康药物研发有限公司 水溶性别孕烯醇酮衍生物及其用途
JP2021529814A (ja) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化学化合物
TW202545902A (zh) * 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
AR118836A1 (es) 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
PH12021552759A1 (en) 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway

Similar Documents

Publication Publication Date Title
JP2022530647A5 (cg-RX-API-DMAC7.html)
RU2020117900A (ru) Модуляторы интегрированного стресса
RU2020117927A (ru) Модуляторы интегрированного стресса
JP2021501790A5 (cg-RX-API-DMAC7.html)
JP2021501779A5 (cg-RX-API-DMAC7.html)
JP2021501781A5 (cg-RX-API-DMAC7.html)
JP2021501787A5 (cg-RX-API-DMAC7.html)
JP2025504859A5 (cg-RX-API-DMAC7.html)
RU2765737C2 (ru) Способ лечения фокально-сегментарного гломерулосклероза
JP2013502431A5 (cg-RX-API-DMAC7.html)
CN113423685A (zh) 整合应激通路的前药调节剂
CA2980395A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
AU2018266640B2 (en) Compounds and methods for treating bacterial infections
JP2017537886A5 (cg-RX-API-DMAC7.html)
JP2025512877A (ja) ハンチントン病を調節するための方法及び化合物
JP2010535211A (ja) 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物
US12612392B2 (en) Compound, pharmaceutical compositions containing same, synthesis method therefor and use thereof
EP2265350A1 (fr) Procede de preparation de cristaux a base d'un ester d'acide gras
CA2569112C (en) Carbapenem antibacterials with gram-negative activity and processes for their preparation
RU2021112336A (ru) Пролекарственные модуляторы интегрированного пути стресса
RU2024122038A (ru) Пролекарственные модуляторы интегрированного пути стресса
PT860165E (pt) Composicoes cosmeticas para a fotoproteccao da pele e/ou dos cabelos a base de uma mistura sinergica de filtros
US20260035355A1 (en) Compound, pharmaceutical composition comprising same, and use thereof
TH2101002115A (th) ตัวปรับควบคุมโปรดรักของวิถีทางความเครียดแบบผสมผสาน
TW202430223A (zh) 用於治療眼部病症之藥物結合物